Is “inflammaging” inevitable?

Based on a recent study in Nature Aging as summarized in the New York Times: Inflammation is a natural immune response that protects the body from injury or infection. Scientists have long believed that long-term, low-grade inflammation — also known as “inflammaging” — is a universal hallmark of getting older. But this new data raises…

Read More

What Does the Federal Government Spend on Health Care?

As Congressional Republicans and President Trump search for trillions of dollars in cuts to mandatory federal spending that could help offset the cost of extending expiring tax cuts, this brief analyzes current support from the federal government for health programs and services, including both spending and tax subsidies as context for those federal budget discussions.

Read More

Es crítico vacunarse contra covid durante el embarazo

Casi el 90% de los bebés que tuvieron que ser hospitalizados con covid-19 tenían madres que no se vacunaron mientras estaban embarazadas, según nuevos datos publicados por los Centros para el Control y Prevención de Enfermedades (CDC). Los hallazgos aparecen en el Informe Semanal de Morbilidad y Mortalidad de la agencia. Los bebés que fueron…

Read More

The Healthcare Sector’s Digital Contagion: Ransomware’s Relentless Grip

In a sector where delays are measured in lives, early detection, lower attacker dwell time, and system-level misdirection can literally save lives. By marrying preemptive and deceptive technologies, organizations can blunt the attack surface while simultaneously exposing hidden threats before damage is done.  The post The Healthcare Sector’s Digital Contagion: Ransomware’s Relentless Grip appeared first…

Read More

Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer

Brepocitinib is on track for pivotal testing after meeting the goals of a proof-of-concept study in cutaneous sarcoidosis, a rare inflammatory skin disorder with no FDA-approved therapies. Roivant Sciences subsidiary Priovant Therapeutics licensed the dual JAK1 and TYK2 inhibitor from Pfizer. The post Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed…

Read More